COVID Pill Tracker

Merck / Molnupiravir First Enrollment

Oct 19, 2020

https://clinicaltrials.gov/ct2/show/NCT04575597

Revive Therapeutics / Bucillamine First Enrollment

Nov 27, 2020

https://revivethera.com/2020/10/revive-therapeutics-provides-update-on-fda-phase-3-clinical-trial-for-bucillamine-in-covid-19/

Alpha and Beta Variants Dominant

Period: Jan 1, 2021 to Jul 7, 2021

https://www.wsj.com/articles/how-the-u-k-became-world-leader-in-sequencing-the-coronavirusgenome-11612011601

Netherlands scientists discover antiviral mechanisms relevant to Bucillamine

Mar 25, 2021

https://www.liebertpub.com/doi/full/10.1089/ars.2020.8247

Merck scraps lead candidate to focus on Molnupiravir in high risk non-hospitalized patients

Apr 15, 2021

https://www.fiercebiotech.com/biotech/merck-cans-one-covid-19-drug-scraps-a-clinical-trial-another

Atea Pharmaceuticals / AT-527 First Enrollment

Apr 28, 2021

https://cen.acs.org/pharmaceuticals/drug-development/Roche-partners-Atea-COVID-19/98/i43

Delta Variant Dominant

Period: Jul 7, 2021 to Jan 1, 2022

https://www.cnbc.com/2021/07/07/cdc-data-shows-delta-is-now-the-dominant-covid-variant-in-the-us.html

Pfizer / Ritonavir First Enrollment

Aug 20, 2021

https://clinicaltrials.gov/ct2/history/NCT04960202?A=1&B=2&C=merged#StudyPageTop

Merck / Molnupiravir High Risk Trial Completion

Oct 1, 2021

https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/

Revive Therapeutics / Bucillamine Primary Completion (Published Estimate)

Oct 31, 2021

https://clinicaltrials.gov/ct2/show/NCT04504734

Pfizer / Ritonavir High Risk Trial Completion

Nov 5, 2021

https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate

Atea Pharmaceuticals / AT-527 Primary Completion (Published Estimate)

Nov 17, 2021

https://clinicaltrials.gov/ct2/show/study/NCT04889040